Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of imidazolyl and dihydroxy ethylamino derivative composition of Psiguadial A to increase of leukocyte

A technology for increasing white blood cells and compositions, applied in the field of preparation and compositions, and can solve the problems of low safety and high toxicity of white blood cells

Inactive Publication Date: 2017-06-13
苏州贺澳德生物医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The existing drugs for the treatment of leukopenia have the problems of high toxicity and low safety. It is of great value to find compounds or lead compounds from natural products and carry out structural modification to obtain their derivatives, so as to obtain potential drugs with high efficiency and low toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of imidazolyl and dihydroxy ethylamino derivative composition of Psiguadial A to increase of leukocyte
  • Application of imidazolyl and dihydroxy ethylamino derivative composition of Psiguadial A to increase of leukocyte
  • Application of imidazolyl and dihydroxy ethylamino derivative composition of Psiguadial A to increase of leukocyte

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0010] The preparation of embodiment 1 compound Psiguadial A

[0011] The preparation method of compound Psiguadial A (I) refers to the literature published by Meng Shao et al. (Meng Shao et al., 2010.Psiguadials A and B, Two Novel Meroterpenoids with UnusualSkeletons from the Leaves of Psidium guajava.Organic Letters 12(2010)5040- 5043) method.

[0012]

Embodiment 2

[0013] The synthesis of the O-bromoethyl derivative (II) of embodiment 2Psiguadial A

[0014] Compound I (474 ​​mg, 1.00 mmol) was dissolved in 20 mL of benzene, tetrabutylammonium bromide (TBAB) (0.16 g), 1,2-dibromoethane (7.520 g, 40.00 mmol) and 12 mL of 50% sodium hydroxide solution. The mixture was stirred at 35 °C for 8 h. After 8 hours, the reaction solution was poured into ice water, extracted twice with dichloromethane immediately, and the organic phase solutions were combined. Then the organic phase solution was washed with water and saturated brine three times successively, then dried with anhydrous sodium sulfate, and finally concentrated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: petroleum ether / acetone=100:0.5, v / v), the brown concentrated elution band was collected and the solvent was evaporated to obtain a brown powder of Compound II (502mg, 73%) ....

Embodiment 3

[0019] The synthesis of the O-(imidazolyl) ethyl derivative (III) of embodiment 3Psiguadial A

[0020] Compound II (344 mg, 0.5 mmol) was dissolved in 25 mL of acetonitrile, anhydrous potassium carbonate (690 mg, 5.0 mmol), potassium iodide (168 mg, 1.0 mmol) and imidazole (3480 mg, 40 mmol) were added thereto, and the mixture was heated to reflux for 2 h. After the reaction was completed, the reaction solution was poured into 25 mL of ice water, extracted twice with an equal amount of dichloromethane, and the organic phases were combined. The combined organic phases were successively washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: petroleum ether / acetone=100:0.4, v / v), the yellow concentrated elution band was collected and the solvent was evaporated to obtain a yellow powder of co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an imidazolyl and dihydroxy ethylamino derivative composition of Psiguadial A to increase of leukocyte, namely, application of a composition of O-(imidazolyl)ethyl and O-(dihydroxy ethylamino)ethyl derivatives of the Psiguadial A to a medicament for increasing the leukocyte. The invention relates to the fields of organic synthesis and pharmaceutical chemistry, in particular to a composition of imidazolyl and the dihydroxy ethylamino derivatives of the Psiguadial A, a preparation method of the composition and application of the composition to preparation of a medicament for increasing the leukocyte. The invention discloses a composition of the imidazolyl and dihydroxy ethylamino derivatives of the Psiguadial A and a preparation method thereof. As proved by a pharmacology experiment, the composition of the imidazolyl and dihydroxy ethylamino derivatives of the Psiguadial A has an effect of increasing the leukocyte, and has a value of developing the medicament for increasing the leukocyte.

Description

technical field [0001] The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a composition, a preparation method and an application thereof. Background technique [0002] Leukopenia is a disease caused by unknown reasons and secondary to other diseases, which can be divided into two categories: primary and secondary. The primary cause is unknown; the secondary cause is believed to be caused by acute infection, physical and chemical factors, blood system diseases, diseases with splenomegaly, connective tissue diseases, allergic diseases, genetic diseases, etc., acquired or Unexplained neutropenia, etc. [0003] The existing drugs for the treatment of leukopenia have the problems of high toxicity and low safety. It is of great value to find compounds or lead compounds from natural products and carry out structural modification to obtain their derivatives, so as to obtain potential drugs with high efficiency and low toxicity. [00...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4178A61K31/335C07D405/14C07D313/08A61P7/00
CPCA61K31/4178A61K31/335C07B2200/07C07D313/08C07D405/14
Inventor 朱磊磊
Owner 苏州贺澳德生物医药科技有限公司